NEAR PATIENT MOLECULAR SOLUTION MARKET ANALYSIS

Leading Companies

Global players involved in near patient molecular solution market

Major companies operating in the global molecular diagnostics include Abbott Laboratories, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Siemens AG, Veridex, LLC, Luminex Corp., and GenMark Diagnostics. Integration of advanced technologies in their product offerings is the major focus of companies competing in near patient molecular solution market. Abbott’s i-STAT Alinity handheld blood testing platform received CE mark in November 2016. Siemens Healthineers acquired Conworx Technology to flesh out its point-of-care informatics capabilities in November 2016. This highly lucrative market is expected to witness fast growth in the near future, fueled by increasing R&D activities by major players in order to differentiate their offerings.

Key Developments

1. Key players are focused on different business strategies such as product launches, in order to expand their product portfolio and gain competitive edge in the market. For instance, in May 2019, Siemens Healthineers, a subsidiary of Siemens AG launched Atellica Solution at 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine held at Barcelona, Spain. Atelllica is designed to address common clinical laboratory challenges.
2. Major players in the market are involved in various business strategies such as gaining regulatory certification, in order to enhance their market presence. For instance, in June 2019, Becton, Dickinson and Company announced CE-IVDD certification for BD COR System in Europe. This high throughput solution is indicated for disease diagnostics that sets new standards in automation for molecular testing.
3. Major players in the market are involved in various business strategies such as gaining regulatory certification, in order to enhance their market presence. For instance, in December 2018, Becton, Dickinson and Company received the U.S. Food and Drug Administration 510(k) clearance for its BD MAX enteric viral panel. This is a molecular diagnostic test for direct qualitative detection and differentiation of enteric viral pathogens.